As a result, Cambridge, Massachusetts-based Alnylam has rescinded all grants of its intellectual property related to current and future Merck development programs, including the partnership’s former co-development programs.
John Maraganore, president and CEO of Alnylam said: “It is fundamentally in our best interests to terminate our Merck collaboration. We wish our colleagues at Merck the best of luck in their efforts.”